Wednesday, November 18, 2026

£1.5bn Landmark Sale of University Firm

Featured Image

Breakthrough in Organ Preservation Technology

A groundbreaking acquisition has taken place in the medical technology sector, with a company specializing in devices that maintain organs outside the human body being purchased by a global leader in medical innovation. This deal marks a significant milestone in the field of organ transplantation and life-saving healthcare solutions.

OrganOx, a company spun off from the University of Oxford, was founded in 2008 by engineering professor Constantin Coussios and transplant surgeon professor Peter Friend. The company has developed advanced organ preservation technology that has already made a profound impact on patient care. According to Prof. Coussios, this technology has helped save the lives of 6,000 patients so far.

The core of OrganOx’s innovation lies in its ability to recreate an environment similar to the human body for organs outside the body. This allows the organs to function as if they were still inside a person. "The machine essentially recreates around the organ an environment that fools it into thinking it is still inside the body," said Prof. Coussios. "So blood-like substance flows through the organ at normal body temperature, the organ is able to breathe and consume nutrients normally, and that means that it is actually functioning outside the body very much as if it were still inside."

This technology, which has been in use since 2013, enables doctors to "test drive" organs before transplantation. This process helps ensure that the organ is healthy and viable for the recipient. "We have over 6,000 patients who are alive today because of this technology—about 10 patients a day and rapidly rising," said Prof. Coussios.

The recent acquisition by Terumo Corporation, a leading medical technology company based in Tokyo, Japan, is expected to accelerate the development and global reach of this life-saving technology. Adam Workman, Head of Investments and Ventures at Oxford University Innovation, described the deal as a "landmark" moment in the industry.

"This was always about producing a sustainable technology the world over, and I will continue to be involved with my cofounder to make sure it finds its home in helping patients around the world," Workman added.

Professor Irene Tracey, Vice-Chancellor of the University of Oxford, expressed her excitement about the sale. "It's just a fantastic story, not just for Oxford and of course for the patients and for the team, but for the UK... it just shows what we can do," she said.

She also highlighted the importance of such deals for students and future innovators. "We make it easy for them to be inspired by people like Constantin and Peter, to have professors teaching them who are serial entrepreneurs and successful ones—that's incredibly inspiring, and that, again, is what we're trying to create in this sector in the UK."

Expanding the Future of Medical Innovation

With the support of Terumo Corporation, OrganOx is now poised to explore new applications for its technology beyond transplantation. This could open up new possibilities for treating various medical conditions and improving patient outcomes globally.

The acquisition not only underscores the potential of medical technology to transform healthcare but also highlights the power of collaboration between academia and industry. As the technology continues to evolve, it is likely to play an even greater role in saving lives and advancing medical science.

For those interested in following the progress of this innovative company, there are multiple platforms where updates and news can be found. However, the focus remains on the transformative impact this technology has had—and will continue to have—on the world of medicine.

0 comments: